Selina J. Chavda

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications

Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0).

Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0).

Journal: Research square
Published: June 12, 2025

Enhanced dynamic risk stratification of smoldering multiple myeloma.

Enhanced dynamic risk stratification of smoldering multiple myeloma.

Journal: Nature medicine
Published: May 19, 2025

Co-operation of MCL-1 and BCL-XL anti-apoptotic proteins in stromal protection of MM cells from carfilzomib mediated cytotoxicity.

Co-operation of MCL-1 and BCL-XL anti-apoptotic proteins in stromal protection of MM cells from carfilzomib mediated cytotoxicity.

Journal: Frontiers in oncology
Published: March 01, 2024

Daratumumab combinations for patients with newly diagnosed and relapsed multiple myeloma.

Daratumumab combinations for patients with newly diagnosed and relapsed multiple myeloma.

Journal: The Lancet. Haematology
Published: August 05, 2023

Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.

Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.

Journal: The Lancet. Haematology
Published: September 07, 2022

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.

Journal: The Lancet. Haematology
Published: July 22, 2022

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma.

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma.

Journal: Blood
Published: February 14, 2022

Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors.

Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors.

Journal: British journal of haematology
Published: October 11, 2021

Applying current smouldering myeloma risk models to a UK single-centre cohort and clinical features at progression.

Applying current smouldering myeloma risk models to a UK single-centre cohort and clinical features at progression.

Journal: British journal of haematology
Published: September 25, 2021

Salvage second autologous stem cell transplant for relapsed multiple myeloma in the novel agent era benefits a subset of patients: single-center UK experience.

Salvage second autologous stem cell transplant for relapsed multiple myeloma in the novel agent era benefits a subset of patients: single-center UK experience.

Journal: Leukemia & lymphoma
Published: August 04, 2021

Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease.

Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease.

Journal: Nature communications
Published: July 17, 2021

Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes.

Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes.

Journal: Nature communications
Published: May 06, 2021
Showing 1-12 of 31

Last Updated: 09/26/2026